|
 |
|
As part of ongoing work to build better medicines for patients, we have entered into two separate agreements with Datavant to link RWD and clinical data sources. Under the first agreement, we are integrating disparate data sets to create rich, longitudinal real-world and clinical datasets to better understand both therapeutics and the holistic patient journey. In the second agreement, Janssen is offering guidance and insights to Datavant’s strategy in relation to new product and service offerings, including efforts to link clinical trial data to real-world evidence to enhance clinical trial execution.
|
 |
|
Janssen has collaborated with Insilico Medicine – an end-to-end, artificial intelligence-driven pharma-technology leader deploying machine learning, deep learning and generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes – to design small molecule hits with the defined properties for several targets we nominated.
|
 |
|
Our collaboration with Iterative Scopes has the potential to help speed study recruitment and enhance our understanding of inflammatory bowel disease (IBD) overall. Iterative Scopes uses AI and computer vision to assess endoscopy recordings, and our partnership enables us to accelerate the development of therapeutics that have the potential to transform patient lives.
|
 |
|
In early 2021, we co-led a Series C investment in Paige AI, a global leader in digital diagnostics focused on providing AI tools that will enable faster and more accurate diagnosis and patient treatment decisions to be made. This investment expands on our development of AI-based capabilities both within and outside of oncology and the delivery of these capabilities to laboratories and clinicians globally.
|
 |
|
Verana Health is a leader in transforming clinical data into actionable Real-World Evidence in ophthalmology and urology. Our collaboration leverages real-world data (RWD) from the American Academy of Ophthalmology Intelligent Research in SIGHT Registry (IRIS® Registry) to address diabetic macular edema. As part of this collaboration, Janssen is also focusing on early-stage prostate cancer with the launch of a pilot program to curate and evaluate de-identified data from the American Urological Association Quality Registry.
|
 |
|
Through our collaboration with VisualDx, a web-based clinical decision support (CDS) company, we can reduce racial and other forms of bias in the clinical decision-making process. Using a new VisualDx application programming interface (API), we can bring CDS into applications that enhance diagnostic accuracy and improve health outcomes, particularly for traditionally marginalized patient populations.
|